Platelets, as anucleate blood cells, play a pivotal role in the pathogenesis of cardiovascular diseases (CVDs), making antiplatelet therapy essential for preventing thrombotic events such as myocardial infarction. Thromboxane A₂ (TXA₂) is a key pro-aggregatory mediator that drives platelet activation. Phosphorylation of vasodilator-stimulated phosphoprotein (VASP) at Ser157 and Ser239 serves as a marker of cyclic nucleotide-mediated inhibitory signaling. The crosstalk between TXA₂ signaling and site-specific VASP phosphorylation in arachidonic acid (AA)-stimulated human platelets remains unclear and requires further investigation. In this study, AA at 60 µM induced maximal platelet activation, as evidenced by ultrastructural changes and increased P-selectin expression. Picotamide, a thromboxane synthase (TXS) inhibitor, effectively reversed AA-induced alterations, including ultrastructural remodeling, P-selectin expression, TXA₂ production, adenosine triphosphate (ATP)-release, mobilization of [Ca²⁺]ᵢ, and integrin αIIbβ3 activation. Importantly, picotamide's inhibition of platelet aggregation was unaffected by adenylate or guanylate cyclase inhibitors, suggesting a mechanism independent of cyclic nucleotide signaling. AA selectively increased VASP phosphorylation at Ser239, but not Ser157. While picotamide alone had no effect, its sequential administration with AA significantly enhanced Ser157 phosphorylation without altering Ser239 levels. These findings suggest that AA differentially regulates VASP phosphorylation sites via distinct mechanisms: Ser239 via a TXA₂-independent pathway associated with inhibitory signaling, and Ser157 via a TXA₂-dependent pathway linked to platelet activation. Finally, picotamide demonstrated superior antithrombotic efficacy compared to aspirin at an equivalent dose, as evidenced by real-time intravital imaging of thrombotic platelet plug formation in vivo. These results highlight TXS inhibition as a promising strategy for modulating platelet activation and thrombosis.
{"title":"Distinct Thromboxane A₂-Dependent Pathways Regulate Arachidonic Acid-Triggered VASP Phosphorylation at Ser239 and Ser157 in Human Platelets: Real-Time Visualization Reveals Superior Antithrombotic Efficacy by Targeting Thromboxane A₂ Signaling over Cyclooxygenase Inhibition.","authors":"Joen-Rong Sheu, Wei-Chieh Huang, Chao-Chien Chang, Chih-Wei Hsia, Chih-Hsuan Hsia, Thanasekaran Jayakumar, Shaw-Min Hou","doi":"10.1002/jcp.70160","DOIUrl":"10.1002/jcp.70160","url":null,"abstract":"<p><p>Platelets, as anucleate blood cells, play a pivotal role in the pathogenesis of cardiovascular diseases (CVDs), making antiplatelet therapy essential for preventing thrombotic events such as myocardial infarction. Thromboxane A₂ (TXA₂) is a key pro-aggregatory mediator that drives platelet activation. Phosphorylation of vasodilator-stimulated phosphoprotein (VASP) at Ser157 and Ser239 serves as a marker of cyclic nucleotide-mediated inhibitory signaling. The crosstalk between TXA₂ signaling and site-specific VASP phosphorylation in arachidonic acid (AA)-stimulated human platelets remains unclear and requires further investigation. In this study, AA at 60 µM induced maximal platelet activation, as evidenced by ultrastructural changes and increased P-selectin expression. Picotamide, a thromboxane synthase (TXS) inhibitor, effectively reversed AA-induced alterations, including ultrastructural remodeling, P-selectin expression, TXA₂ production, adenosine triphosphate (ATP)-release, mobilization of [Ca²⁺]ᵢ, and integrin α<sub>IIb</sub>β<sub>3</sub> activation. Importantly, picotamide's inhibition of platelet aggregation was unaffected by adenylate or guanylate cyclase inhibitors, suggesting a mechanism independent of cyclic nucleotide signaling. AA selectively increased VASP phosphorylation at Ser239, but not Ser157. While picotamide alone had no effect, its sequential administration with AA significantly enhanced Ser157 phosphorylation without altering Ser239 levels. These findings suggest that AA differentially regulates VASP phosphorylation sites via distinct mechanisms: Ser239 via a TXA₂-independent pathway associated with inhibitory signaling, and Ser157 via a TXA₂-dependent pathway linked to platelet activation. Finally, picotamide demonstrated superior antithrombotic efficacy compared to aspirin at an equivalent dose, as evidenced by real-time intravital imaging of thrombotic platelet plug formation in vivo. These results highlight TXS inhibition as a promising strategy for modulating platelet activation and thrombosis.</p>","PeriodicalId":15220,"journal":{"name":"Journal of Cellular Physiology","volume":"241 3","pages":"e70160"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12969544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oscillations in intracellular Ca2+ [Ca2+]i are essential for mouse oocyte activation following fertilization. These [Ca2+]i oscillations also induce repetitive hyperpolarizations in the membrane potential (Em). The present study aimed to identify the channels underlying the Em hyperpolarizations. Sulfhydryl reagents such as thimerosal, that oxidize the IP3-R channel, mimic the physiological changes at fertilization by eliciting simultaneous Em changes and [Ca2+]i oscillations. Thimerosal-induced Em and [Ca2+]i changes were prevented by the non-specific Ca2+-activated Cl- channel (CaCC) inhibitors DIDS and NFA, as well as the TMEM16A/Anoctamin 1 CaCC specific inhibitor, T16Ainh-01. The K+ channel blocker TEA, and voltage-gated Cl- channel blocker 9AC failed to inhibit the Em or [Ca2+]i changes. TMEM16A protein was expressed in all stages of mouse preimplantation development, being localized at the plasma membrane in oocytes. Culture of zygotes in the TMEM16A inhibitor prevented development to the blastocyst stage. In summary, we present the first evidence for CaCC channels, namely TMEM16A, being critical for the initiation of Em hyperpolarisations in mouse oocytes.
{"title":"TMEM16A Contributes to Calcium-Activated Chloride Currents and Membrane Potential Changes in the Mouse Oocyte.","authors":"Sarah Dalati, Vanessa J Jones, Margot L Day","doi":"10.1002/jcp.70159","DOIUrl":"https://doi.org/10.1002/jcp.70159","url":null,"abstract":"<p><p>Oscillations in intracellular Ca<sup>2+</sup> [Ca<sup>2+</sup>]<sub>i</sub> are essential for mouse oocyte activation following fertilization. These [Ca<sup>2+</sup>]<sub>i</sub> oscillations also induce repetitive hyperpolarizations in the membrane potential (Em). The present study aimed to identify the channels underlying the Em hyperpolarizations. Sulfhydryl reagents such as thimerosal, that oxidize the IP3-R channel, mimic the physiological changes at fertilization by eliciting simultaneous Em changes and [Ca<sup>2+</sup>]<sub>i</sub> oscillations. Thimerosal-induced Em and [Ca<sup>2+</sup>]<sub>i</sub> changes were prevented by the non-specific Ca<sup>2+</sup>-activated Cl<sup>-</sup> channel (CaCC) inhibitors DIDS and NFA, as well as the TMEM16A/Anoctamin 1 CaCC specific inhibitor, T16Ainh-01. The K<sup>+</sup> channel blocker TEA, and voltage-gated Cl<sup>-</sup> channel blocker 9AC failed to inhibit the Em or [Ca<sup>2+</sup>]<sub>i</sub> changes. TMEM16A protein was expressed in all stages of mouse preimplantation development, being localized at the plasma membrane in oocytes. Culture of zygotes in the TMEM16A inhibitor prevented development to the blastocyst stage. In summary, we present the first evidence for CaCC channels, namely TMEM16A, being critical for the initiation of Em hyperpolarisations in mouse oocytes.</p>","PeriodicalId":15220,"journal":{"name":"Journal of Cellular Physiology","volume":"241 3","pages":"e70159"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12974648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147433091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daria Di Molfetta, Marilena Ardone, Francesca Fracasso, Maria Raffaella Greco, Grazia Tamma, Mariangela Centrone, Maria Barile, Maria Tolomeo, Alessia Nisco, Stephan Joel Reshkin, Rosa Angela Cardone
Branching morphogenesis is a key process for constructing the tree-like architecture of multiple organs. The mechanisms regulating pancreatic ductal morphogenesis are still poorly understood, especially in the context of the particular pH dynamics of this organ. Indeed, ductal cells periodically release an alkaline juice to balance stomach acidity during digestion. This leads to a drop in extracellular pH (pHe) in the extracellular matrix (ECM) to maintain intracellular pH (pHi) homeostasis. Among the transporters involved in pH regulation, NHE1 also regulates epithelial branching morphogenesis in various tissues/organs. However, neither the effect of the changing pHe nor the role of NHE1 in branching morphogenesis has been investigated in a physiomimetic model in the human pancreas. Here, using 3D organotypic cultures of human pancreatic ductal cells (HPDE), we found that cells seeded on a Matrigel rich-ECM resembling normal ECM formed branched duct-like structures, which did not form on a more fibrotic Collagen I-rich ECM. Further, these cells overexpressed NHE1 mainly at the basolateral membrane. Ductal morphogenesis was affected by acidic pHe (pHe 6.7), which determined a hyper-branched network, and this was further increased by the inhibition of NHE1. We conclude that ECM composition and extracellular acidosis modulate branching morphogenesis in pancreatic ductal HPDE cells via NHE1 activity.
{"title":"Extracellular pH and NHE1 Regulate Ductal Branching Morphogenesis in Organotypic Cultures of Human Pancreatic Duct Epithelial Cells.","authors":"Daria Di Molfetta, Marilena Ardone, Francesca Fracasso, Maria Raffaella Greco, Grazia Tamma, Mariangela Centrone, Maria Barile, Maria Tolomeo, Alessia Nisco, Stephan Joel Reshkin, Rosa Angela Cardone","doi":"10.1002/jcp.70156","DOIUrl":"10.1002/jcp.70156","url":null,"abstract":"<p><p>Branching morphogenesis is a key process for constructing the tree-like architecture of multiple organs. The mechanisms regulating pancreatic ductal morphogenesis are still poorly understood, especially in the context of the particular pH dynamics of this organ. Indeed, ductal cells periodically release an alkaline juice to balance stomach acidity during digestion. This leads to a drop in extracellular pH (pHe) in the extracellular matrix (ECM) to maintain intracellular pH (pHi) homeostasis. Among the transporters involved in pH regulation, NHE1 also regulates epithelial branching morphogenesis in various tissues/organs. However, neither the effect of the changing pHe nor the role of NHE1 in branching morphogenesis has been investigated in a physiomimetic model in the human pancreas. Here, using 3D organotypic cultures of human pancreatic ductal cells (HPDE), we found that cells seeded on a Matrigel rich-ECM resembling normal ECM formed branched duct-like structures, which did not form on a more fibrotic Collagen I-rich ECM. Further, these cells overexpressed NHE1 mainly at the basolateral membrane. Ductal morphogenesis was affected by acidic pHe (pHe 6.7), which determined a hyper-branched network, and this was further increased by the inhibition of NHE1. We conclude that ECM composition and extracellular acidosis modulate branching morphogenesis in pancreatic ductal HPDE cells via NHE1 activity.</p>","PeriodicalId":15220,"journal":{"name":"Journal of Cellular Physiology","volume":"241 3","pages":"e70156"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12954557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bernareggi Annalisa, Zhang Wen Ru, Sanchez-Sanchez Laura, Norbedo Alessia, Fracassi Anna, Lucafò Marianna, Sciancalepore Marina, Alberto Griffoni, Russell K William, Taglialatela Giulio, Lorenzon Paola, Limon Agenor
PIEZO1 are mechanically-activated ion channels expressed in many cell types. Their pharmacological activation by the selective agonist Yoda1 has been reported to favor skeletal muscle regeneration by controlling the fate of myogenic precursors cells, but the underlying mechanisms remain largely unknown. Hereby, we investigated the possibility that PIEZO1 could control the release of small extracellular vesicles in myogenic C2C12 cells. Myoblasts and differentiated myotubes were treated with the PIEZO1 agonist Yoda1 (5 μM) for 24 hours. Released small extracellular vesicles were isolated by ultracentrifugation methods, and characterized by Western blotting, Nano Tracking and proteomic analysis. Pharmacological activation of PIEZO1 showed cell-type-specific effects: In myoblasts, Yoda1 treatment did not significantly affect the size or release of the small extracellular vesicles and resulted in only minor alterations to their proteomic profile. In myotubes Yoda1 treatment significantly increased small extracellular vesicles release and caused subtsantial alterations to the proteomic cargo. Notably, small extracellular vesicles released from both myoblasts and myotubes under PIEZO1 activation promoted myotube formation, though they did so through different capacities. Interestingly, in myotubes, Yoda1 also increased the expression of PIEZO1 protein of the vesicles suggesting a different biogenesis in undifferentiated and differentiated myogenic cells. Here, we propose PIEZO1 as a key element in controlling the release of small extracellular vesicles in myogenic precursors. Given the critical role of small extracellular vesicles in intercellular communication during muscle regeneration, our findings contribute to a better understanding of the role of PIEZO1 in the physiopathology of skeletal muscle tissue.
{"title":"PIEZO1 Channels Modulate the Small Extracellular Vesicle Release in C2C12 Cells.","authors":"Bernareggi Annalisa, Zhang Wen Ru, Sanchez-Sanchez Laura, Norbedo Alessia, Fracassi Anna, Lucafò Marianna, Sciancalepore Marina, Alberto Griffoni, Russell K William, Taglialatela Giulio, Lorenzon Paola, Limon Agenor","doi":"10.1002/jcp.70155","DOIUrl":"10.1002/jcp.70155","url":null,"abstract":"<p><p>PIEZO1 are mechanically-activated ion channels expressed in many cell types. Their pharmacological activation by the selective agonist Yoda1 has been reported to favor skeletal muscle regeneration by controlling the fate of myogenic precursors cells, but the underlying mechanisms remain largely unknown. Hereby, we investigated the possibility that PIEZO1 could control the release of small extracellular vesicles in myogenic C2C12 cells. Myoblasts and differentiated myotubes were treated with the PIEZO1 agonist Yoda1 (5 μM) for 24 hours. Released small extracellular vesicles were isolated by ultracentrifugation methods, and characterized by Western blotting, Nano Tracking and proteomic analysis. Pharmacological activation of PIEZO1 showed cell-type-specific effects: In myoblasts, Yoda1 treatment did not significantly affect the size or release of the small extracellular vesicles and resulted in only minor alterations to their proteomic profile. In myotubes Yoda1 treatment significantly increased small extracellular vesicles release and caused subtsantial alterations to the proteomic cargo. Notably, small extracellular vesicles released from both myoblasts and myotubes under PIEZO1 activation promoted myotube formation, though they did so through different capacities. Interestingly, in myotubes, Yoda1 also increased the expression of PIEZO1 protein of the vesicles suggesting a different biogenesis in undifferentiated and differentiated myogenic cells. Here, we propose PIEZO1 as a key element in controlling the release of small extracellular vesicles in myogenic precursors. Given the critical role of small extracellular vesicles in intercellular communication during muscle regeneration, our findings contribute to a better understanding of the role of PIEZO1 in the physiopathology of skeletal muscle tissue.</p>","PeriodicalId":15220,"journal":{"name":"Journal of Cellular Physiology","volume":"241 3","pages":"e70155"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12989915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147463367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}